Biodexa Pharmaceuticals (ADR) (BDRX)
Advancing licensed therapies for familial adenomatous polyposis, treatment-resistant GIST, and type 1 diabetes.
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. As of today, 87 of a planned 168 subjects have been recruited into the Serenta trial.
Result of General Meeting
July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that at its General Meeting held earlier today, all four resolutions put to the Company's shareholders were duly passed.
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
July 28, 2026 Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has held its first round table meeting in Paris, France as part of expanding its support for Familial Adenomatous Polyposis (FAP) patients and prescribers. The sharing of experience and expertise amongst patients, patient advocacy groups and clinicians is informing Biodexa's goal of improving outcomes and quality of life for FAP patients.
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a $0.8 million registered offering (the “Registered Offering”), a $1.0 million concurrent private placement (the “Private Offering”) and a $1.7 million warrant inducement (the “Warrant Inducement” and, together with the Registered Offering and the Private Offering, the “Offerings”) utilizing existing share capital authorities. The Registered Offering consists of 282,952 American depositary shares (“ADSs”) (or pre-funded warrants in lieu thereof) at an offering price of $2.85 per ADS.
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has received approval from Health Canada to expand its registrational Phase 3 trial in familial adenomatous polyposis (“FAP”) into Canada. The Phase 3 study, branded Serenta, is already up and running in a total of 29 active recruiting clinical centers spread across the US and five countries in Europe.
Biodexa issues letter to Shareholders
May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company's share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder's rights.
Preliminary Results for the Year Ended 31 December 2025
March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180 www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 under development for Gastrointestinal Stromal Tumors (GIST) and tolimidone, under development for the treatment of type 1 diabetes.
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Scheduled to Reverse Split on Monday, April 6th
Shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ: BDRX) are set to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 3rd. Biodexa Pharmaceuticals Price Performance
ADR Ratio Change
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026.
Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX)
Radiopharm Theranostics (NASDAQ: RADX - Get Free Report) and Biodexa Pharmaceuticals (NASDAQ: BDRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation. Analyst Ratings This is a summary of
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
March 9, 2026 Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life's a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization's vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life's a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated exclusively to FAP, providing essential resources, community support, and awareness for patients and families facing this rare genetic condition that causes hundreds of precancerous polyps and carries a near-100% risk of colorectal cancer without intervention.
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ: BDRX - Get Free Report) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 43,229 shares, a drop of 91.3% from the December 15th total of 494,378 shares. Approximately 7.0% of the shares of the stock are sold
Biodexa Announces Pricing of $10 Million Public Offering
December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a best efforts public offering of an aggregate of (i) 157,000 units (the “ADS Units”), with each unit consisting of (A) one American depositary share (representing 100,000 of the Company's ordinary shares) (“ADSs”), and (B) two Series L warrants, each to purchase one ADS (the “Series L Warrants”), and (ii) 2,891,781 pre-funded units (the “Pre-Funded Units”), with each Pre-Funded Unit consisting of (A) one pre-funded warrant to purchase one ADS and (ii) two Series L Warrants. The combined public offering price of each ADS Unit is $3.28, and the combined public offering price of each Pre-Funded Unit is $3.2799.
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of the first three patients by the University of Bonn, Germany into its pivotal Phase 3 Serenta trial of eRapa in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. Commenting, Dr Robert Hüneburg, gastroenterologist and lead investigator at the University Hospital, Bonn (Germany) said “We are pleased to be the first European center to be activated and to have enrolled the first three patients into the European arm of the Serenta trial.
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis (FAP). This marks the first European site activation for the registrational Serenta trial, representing a major milestone in expanding FAP treatment options to European patients who currently have no approved non-surgical therapeutic alternatives.
Interim results for the six months ended June 30, 2025
September 12, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No.
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic Options By: Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / September 8, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a late clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, has launched its registrational Phase 3 trial of eRapa - its proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), a debilitating disease of the lower GI tract.
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of the first two patients by the Pan American Center for Oncology Trials in San Juan, Puerto Rico into its pivotal Phase 3 Serenta trial of eRapa in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. The only current treatment option is sequential resection of the gastrointestinal tract.
ADR Ratio Change Effective
July 31, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces the previously announced ratio change of its American Depositary Receipts (“ADR”) from one (1) ADR representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) ADR representing one hundred thousand (100,000) ordinary shares (the "Ratio Change"), became effective at the open of business on July 31, 2025 (U.S. Eastern Time). For ADR holders, the Ratio Change will have the same effect as a one-for-ten reverse ADR split.